Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4552W HIGH $2.94
Volume
10.22 K
Value Traded
15.76 K
Short % Float
0.28%
Days to Cover
1.0
0%Week
-23.05%1 Month
+12.42%3 Month
-20.37%6 Month
-91.52%5 Year
-94.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.91 M
EPS (TTM)
-1.09
P/E Ratio
-
Ent. Value
5.18 M
Total Shares
4.60 M
Float Shares
3.78 M
Insiders
17.86%
Institutions
2.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BMRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Biomerica, Inc.
Past FDA Catalysts and PDUFA Decisions
How BMRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Biomerica, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BMRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| inFoods IBS test | Irritable Bowel Syndrome (IBS) | 2025-06-05 | treatment group responder: 59.6%; control group responder: 42.2%; IBS C treatment group: 67.1%; IBS C control group: 35.8%; IBS M treatment group: 66.0%; IBS M control group: 29.5%Read More | Biomerica’s inFoods IBS Clinical Study Results Published in June Issue of GastroenterologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MOATAZEDI DAVIDDirector | Buy | 10,000 40,625 held | $1.60 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BMRA for Q2 2026. | ||||
BMRA Institutional Ownership Trends
BMRA Short Interest
Shares sold short, counted twice a month.
0.28%
Short % of Float
of tradable shares sold short
10.5K
Shares Sold Short
-62.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
14.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BMRA ranks across every disease it competes in
Competitive Position is a premium feature
See how BMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBMRA News
BMRABiomerica Reports First Quarter Fiscal 2027 Financial Results
Biomerica, Inc. reported its first quarter fiscal 2027 financial results, highlighting a 120% increase in Medicare-related test orders for its inFoods® IBS product. The company also noted a significant rise in over-the-counter sales and a doubling of cash reserves. However, net sales and gross profit margins saw declines compared to the previous year, leading to an increased operating loss.
Read more →BMRABiomerica Reports Fiscal 2026 Year-End Financial Results
Biomerica reported its fiscal 2026 financial results, highlighting a 17% increase in Q4 net sales and a 24% improvement in net loss. The company successfully processed Medicare claims for its inFoods IBS product, which is expected to expand its market reach. However, full-year net sales decreased, primarily due to lower clinical laboratory sales and increased operating expenses.
Read more →BMRA▲ +24.3%on this newsshared move
Biomerica Announces $2.23 Million Financing
Biomerica, Inc. has announced a private placement financing of approximately $2.23 million through the sale of 1,393,705 shares at $1.60 each. The financing aims to enhance the company's balance sheet and support ongoing evaluations of strategic opportunities, including potential partnerships and acquisitions. B. Riley Securities will act as the exclusive financial advisor for these strategic pursuits.
Read more →BMRABiomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica, Inc. has entered a Master Services Agreement worth $1.75 million with a confidential life sciences company for the development of IVD assays. The agreement will be executed over multiple Statements of Work and is set for an initial three-year term. This engagement allows Biomerica to utilize its established expertise in assay development while maintaining its focus on its primary product, inFoods® IBS.
Read more →BMRABiomerica’s inFoods IBS Data Accepted for Presentation at Digestive Disease Week 2026
Biomerica, Inc. announced that their inFoods IBS diagnostic-guided therapy has been accepted for presentation at the upcoming Digestive Disease Week 2026. This event, being the largest in gastroenterology, showcases the increasing interest in non-pharmacologic dietary management for irritable bowel syndrome (IBS). The study, conducted by leading institutions, builds on prior promising trial results indicating significant symptom relief for patients who eliminated identified food triggers. The acceptance of this presentation marks a significant recognition of inFoods IBS's potential in addressing IBS treatment needs.
Read more →BMRABiomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Biomerica has received confirmation from the Medicare Administrative Contractor that claims for its inFoods® IBS test will be reviewed on an individual basis, paving the way for Medicare coverage. The test, which identifies food triggers for IBS, is supported by strong clinical evidence and has a pre-established payment rate of $300. This development is expected to facilitate revenue generation for Biomerica starting January 1, 2026.
Read more →BMRABiomerica Launches inFoods IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
Biomerica, Inc. has launched its inFoods® IBS platform in Canada, marking the company's first commercial foray into this market. The launch is facilitated through partnerships with Phoenix Airmid Biomedical for distribution and CanAlt Health Labs for laboratory services. With an estimated 5 million Canadians affected by IBS, the inFoods® platform aims to meet the substantial and underserved demand for non-pharmaceutical treatment options. Clinical data supporting the product highlights its potential effectiveness in addressing gastrointestinal symptoms.
Read more →BMRABiomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its third quarter fiscal 2026 financial results, highlighting positive real-world data for its inFoods®IBS product, which showed significant pain and bloating reduction in IBS patients. The company also announced a national Medicare payment rate for inFoods®IBS, enhancing patient access. Despite a decrease in net sales and an increase in net loss, European revenue grew by 45%, reflecting strong market demand.
Read more →BMRABiomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
Biomerica has achieved a significant milestone by receiving its first commercial order for its Hp Detect™ test from one of the largest clinical laboratory chains in Europe. The order is particularly important as it positions Biomerica for potential broader adoption of its diagnostic products within the European market, especially given the high prevalence of H. pylori infections. The company expects this initial order to lead to additional recurring orders as its product becomes part of the customer's routine testing protocol. The announcement underscores the growing commercial viability of Biomerica's diagnostic products amidst rising public health concerns related to H. pylori.
Read more →BMRABiomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Biomerica has received MHRA registration for its hp+detect™ diagnostic test, enabling commercial sales in Great Britain. This test detects H. pylori, a significant health concern linked to gastric cancer. The company is actively pursuing partnerships in the UK market to enhance access to this diagnostic tool. The registration marks a significant milestone for Biomerica's international expansion.
Read more →BMRA▼ -5.1%on this news
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Biomerica reported that 59.4% of patients achieved clinically meaningful abdominal pain reduction and 68.1% saw bloating improvement with inFoods IBS therapy. These results come from a real-world study of 69 patients using the FDA-recognized responder endpoint. The company also announced a $300 national Medicare payment rate for the test, effective January 1, 2026. This pricing establishes a benchmark for negotiations with private commercial insurers.
Read more →BMRAVietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease screening test. This at-home test aims to improve early detection of colorectal cancer, addressing a significant public health issue in Vietnam, where the survival rate for colorectal cancer is notably low. The company plans to collaborate with a major distributor to ensure widespread availability across various sales channels.
Read more →BMRABiomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica reported its financial results for the second quarter of fiscal 2026, showing a decrease in net sales to $1.21 million compared to $1.64 million in the prior year. The company is transitioning to higher-margin diagnostic products, which has led to a strategic pivot affecting current revenues. Despite a net loss of $1.32 million, management remains optimistic about future growth driven by new product launches and partnerships.
Read more →BMRABiomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
Biomerica has announced that the Centers for Medicare & Medicaid Services (CMS) set a national Medicare payment rate of $300 for its inFoods IBS test, effective January 1, 2026. This decision follows the approval of a unique CPT code for the test, enhancing patient access and commercial growth potential. The inFoods IBS test aims to address the unmet needs of IBS patients by identifying food triggers and providing targeted dietary recommendations.
Read more →BMRAEgyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid screening tests. This includes tests for colorectal, breast, and prostate cancers, as well as chronic diseases like kidney disease and H. pylori infection. The tests aim to facilitate early detection and are designed for easy use in various settings, addressing significant health needs in Egypt.
Read more →BMRABiomerica’s inFoods IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica, Inc. has announced that its inFoods IBS diagnostic-guided therapy product is featured in the Fall 2025 issue of Biotherapeutics Quarterly. The article highlights results from a large clinical trial indicating that the inFoods assay effectively identifies dietary triggers for IBS, leading to significant symptom relief. The study demonstrated a higher percentage of pain reduction in patients following the inFoods-guided diet compared to a placebo group, showcasing a promising direction for precision medicine in managing IBS. The innovative approach aims to enhance patient experience by minimizing unnecessary dietary restrictions.
Read more →BMRABiomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Biomerica, Inc. has announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to cater to increasing market demand. The company aims to enhance its capabilities, providing comprehensive support from concept to commercial manufacturing. With over 40 years of experience, Biomerica is well-positioned to assist diagnostic innovators while its updated website aims to improve partner engagement.
Read more →BMRA▲ +5.2%on this news
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
Biomerica, Inc. has entered a marketing services agreement with Henry Schein, Inc. to promote its inFoods® IBS test across the U.S., excluding New York. This partnership aims to enhance the adoption of a non-drug therapy for IBS, leveraging Henry Schein's extensive distribution network. A recent clinical study published in Gastroenterology supports the test's efficacy, particularly for IBS-M patients.
Read more →BMRABiomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its financial results for the first quarter of fiscal 2026, revealing net sales of $1.4 million, a decrease from $1.8 million in the prior year. Despite lower sales, the company saw an increase in gross profit due to a favorable product mix. Operating expenses also decreased, leading to an improved operating loss of $1.1 million. Notably, Biomerica achieved a net profit of approximately $2,000, contrasting with a net loss of $1.3 million in the same quarter last year.
Read more →BMRAGary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Inc. has appointed Gary Huff, former CEO of LabCorp Diagnostics, to its Board of Directors. Huff's extensive experience in the diagnostics industry is expected to contribute to Biomerica's growth and innovation, particularly with its inFoods® IBS product aimed at improving patient care for irritable bowel syndrome. His strategic vision is anticipated to drive sustainable growth for the company.
Read more →About Biomerica, Inc.
Headquarters17571 VON KARMAN AVENUE, IRVINE, CA, 92614
BIOPHARMAWATCH ELITE PLUS
Trade the next BMRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime